CONFIDENTIAL

3H Medi Solution
Global Capabilities

Oncology Department

some pretty spectacularstatistics..

50+

Research100

KOLs

1 MillionAccesses

20,000150

Patients

80+EventsTrialsv

2

KOL (Key Opinion Leader) agreeing with Oncolo Team

100+ KOLs
Over 100 cancer specialists support
Many professors/deans

Oncolo Medical Supporter
A medical representative who agreed to cooperatewith 3H Oncolo information site.

Copyright © 3H Medi Solution3E-mail members
1Million Users Visit ONCOLO® per Month.
General7%
Pharma28%

Stage I
26％
Stage IV
40％

Patients
25%

Stage II
14％

Stage III20％

Family13%

Healthcare
Associates4%

MedicalStaff Doctor
8%15%Lung Cancer
21.5% Cervical Cancer
1.4%
Breast Cancer
17.8% Neuroendocrine Tumor 1.2%
Colorectal Cancer
7.9% Thyroid Cancer
1.2%
Stomach Cancer
7.0% Brain Tumor
1.2%
Ovarian Cancer
4.5% Malignant Mesothelioma 1.2%
Pancreatic Cancer
3.7% Melanoma
0.6%
Prostate Cancer
2.7% Laryngeal Cancer
0.4%
Kidney Cancer
2.7% Malignant Lymphoma
2.5%
Uterine Body Cancer 2.3% Leukemia
2.1%
Liver Cancer
2.1% Multiple Myeloma
1.2%
Canteen Cancers
2.1% Other
11.2%Bladder Cancer
1.6%

but also by many pharmaceutical/medical related staffs
Copyright © 3H medi solutionv Our website is visited not only by patients,

4

寄付団体

患者団体
仲間

家族

KOL
看護師

Esophageal cancer
介護⼠

学会

GIST

Head and neck squamous cell carcinoma

患者

悔しい

マスコミ

Small-cell lung cancer

研究団体

臨床研究

国

Rare cancer (basket）

諦めないオンコロジスト

Low-grade Non-Hodgkin lymphoma

性別

頑張る

ありがとう

Muscle layer non-invasive bladder cancer

ホスピス
Muscle-invasive bladder cancer

幸せ ごめん

がんサバイバー知⼈

Triple-negative breast cancer

緩和医療

Clinical Trial Advertising（Mar 2016～Till Now）
⽣きたい
癌種
地域

時間軸

医療費

BRCA breast cancer

保険会社

臨床試験
製薬会社

Non-metastatic castration-resistant
prostate cancer

年齢

研究者

Malignant pleural mesothelioma

Achievement（include plans）︓More than 80 trials:
Brain tumor︓2、Head and neck cancer︓1、
ARO

医師

MR

Salivary gland cancer︓1、Non-small cell lung cancer︓9、Small-cell lung cancer︓3、Breast cancer︓5、Malignant
pleural mesothelioma︓5、Esophageal cancer︓2、Gastric cancer︓2、Hepatocellular carcinoma︓1、Renal cellcarcinoma︓2、Bladder cancer︓3、Colorectal cancer︓1、GIST︓1、Prostate cancer︓1、Malignant lymphoma︓6、Leukemia︓7、Multiple myeloma︓1、Rare cancer basket study︓1、Melanoma︓2、Unknown primary cancer︓1、SolidPV
PMDA
cancer︓1、Bone metastasis sarcoma︓1、uterine carcinosarcoma︓1、Small intestine adenocarcinoma︓1、Glioma︓1
臨床検査技師、Urothelial
cancer︓2、Glioblastoma︓1

病院

CRA

薬剤師

PMCRO

CRC

・Ads for hematologic cancer are increasing and has a very high responsive rate
SMO
CMC rate
・Ads for immune checkpoint inhibitor is decreasing but has a high responsive・Connections with sites go up and medical investigator trials are increasing as wellCopyright © 3H Medi Solution

5Incurable diseases・Rare disease information site『RareS.
』◆Rare disease information site RareS.
◆URL︓https://raresnet.com/◆since︓2018 Feb〜
◆Relation︓NPO incurable disease network◆page views︓20,000/month◆active users︓1,000/month◆Patient Organization︓109● latest news︓Collect and publish news related to rare diseases● various types of rare diseases︓designated rare diseases＋rare cancers, pediatric chronic
specific diseases● clinical trial information︓posting information about studies which are recruiting participants.
● event information︓information on national events held by various organizations.
● Incurable disease medical liaison council･Posting information on updates of theseorganizations
Copyright © 3H Medi Solution

Medical Information Provision Formeconsent(planned)

Completed
VirtualStudy for
ONCOLOGY

analysis
Alert

Study Details: Siteless Virtual Study of Adverse Event Monitoring Applications in Cancer Patients
site less Virtual Study for Validation of Adverse Events Monitoring Application in Oncology
Indication: Projected number of subjects with advanced cancer
Patients: 100 subjects
Study Period: November 2019 to March 2020
Objectives: P-Guardian Systems Validation and Exploration of Changes in Patients' Quality of Life
Scheduled scale: PRO-CTCAE(Weekly), FACT-G(Monthly)
Sensor-Acquisition Scale: Activity (Calorie, METs), SpO2, Heart Rate, Sleeps

Patient Insight //Cancer treatment patients
Project Summary //SponsorGlobal Pharma

Support from 3H

Quantitative Research

Timing ofconsultation

Considering Disease AwarenessTargetOngoing treatment Cancer Patients# of sample

n=287(BC,LC,CML,RCC)

Target area

All Japan

Medias used

OncoloImpressive Number //Expert Analysis //üüüü

There are patients who can not consult their doctor about
their pain and anxiety.
Patients usually get the care/treatment after consultation
but there are the cases where care/treatment was notprovided as well as even after receiving there was not
improvement some said. So it is necessary to improve thecurrent situation.
After consultation 80% of patients were satisfied however
solving the pain & anxiety was key points
By communicating to doctor about their pain and anxiety toand getting the appropriate care which resulted in
acceptance of longer duration of cancer treatment.

v

90Japanese Cancer Patients were interviewed
to know about their pain and their caregiving condition whether it is sufficient or not.
Those who felt uneasy even once was 89.9%, wheremost of them had an anxiety experience. In addition,
65.5% answered that they felt pain even once, andthose who had pain during cancer treatments were over60%.
There were more than half of patients who answeredthat “pain” and “anxiety” were affecting their cancer
treatment. Further, half of total patient answered thatthey have consulted their doctors about pain where only
20% of patients replied that they have consulted to theirdoctors for anxiety. However 41.7% replied that they
had not got care after consulted with doctor about theiranxiety.

Copyright © 3H8

Thank you
To know more please contact:

imran@3h-ms.co.jp